Longitudinal Trajectories of the Cognitive Function Index in the A4 Study
Open Access
- 27 June 2024
- journal article
- research article
- Published by Elsevier in The Journal Of Prevention of Alzheimer's Disease
- Vol. 11 (4) , 838-845
Abstract
The Anti-Amyloid in Asymptomatic Alzheimer’s Disease (A4) Study failed to show a treatment benefit with solanezumab, but the longitudinal consequenceKeywords
This publication has 20 references indexed in Scilit:
- The Utility of the Cognitive Function Instrument (CFI) to Detect Cognitive Decline in Non-Demented Older AdultsJournal of Alzheimer’s Disease, 2017
- Tracking Early Decline in Cognitive Function in Older Individuals at Risk for Alzheimer Disease DementiaJAMA Neurology, 2015
- The Preclinical Alzheimer Cognitive CompositeJAMA Neurology, 2014
- A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's diseaseAlzheimer's & Dementia, 2014
- Effect of Knowledge of APOE Genotype on Subjective and Objective Memory Performance in Healthy Older AdultsAmerican Journal of Psychiatry, 2014
- Development of Alternate Paragraphs for the Logical Memory Subtest of the Wechsler Memory Scale-IVApplied Neuropsychology: Adult, 2013
- Solanezumab for the treatment of mild-to-moderate Alzheimer’s diseaseExpert Review of Clinical Immunology, 2012
- Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer's diseaseJournal of the International Neuropsychological Society, 2008
- ADCS Prevention Instrument Project: The Mail-In Cognitive Function Screening Instrument (MCFSI)Alzheimer Disease & Associated Disorders, 2006
- “Mini-mental state”Journal of Psychiatric Research, 1975